Cell News and Research

RSS

Critically ill children with flu-like symptoms should be treated preemptively with antiviral medications

Lessons learned from the first 13 children at Johns Hopkins Children's Center to become critically ill from the H1N1 virus show that although all patients survived, serious complications developed quickly, unpredictably, with great variations from patient to patient and with serious need for vigilant monitoring and quick treatment adjustments.

8 Jan 2010

Business leaders should continue to monitor H1N1 risk management to alleviate major impact on costs and revenues

The swine flu pandemic may be off the media’s radar screen, but business executives can ill afford to rest easy. Experts from the National Center for Critical Incident Analysis (NCCIA), who have studied how to respond to pandemics and bioterrorism attacks, warn that executives need to continue to monitor and manage unknown risk factors that might cause the flu to have a major impact upon costs and revenues.

8 Jan 2010

Chinese researchers become the world's fifth most prolific contributors to regenerative medicine

Chinese researchers have become the world's fifth most prolific contributors to peer-reviewed scientific literature on clock-reversing regenerative medicine even as a skeptical international research community condemns the practice of Chinese clinics administering unproven stem cell therapies to domestic and foreign patients.

8 Jan 2010

Ligand Pharmaceuticals receives $1 million as payment from N. V. Organon

Ligand Pharmaceuticals Incorporated announced today that it has received a $1 million milestone payment from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that expired on December 31, 2009.

8 Jan 2010

Scientists identify gene underlying a disease that causes temporary paralysis of skeletal muscle

Scientists have identified a gene underlying a disease that causes temporary paralysis of skeletal muscle. The finding, they say, illustrates how investigations of rare genetic diseases can drive insights into more common ones.

8 Jan 2010

CSHL scientists explain how initiation of DNA replication is coordinated and controlled by kinase proteins

Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered how a protein long known to be an essential activator of DNA replication actually triggers this process in cells.

8 Jan 2010

Zebrafish publishes special issue on cancer biology

The zebrafish, a translucent fish often used as a model of human development and disease, offers unique advantages for studying the cause, growth, and spread of tumors using strategies and methods presented in the current "Cancer Biology" special issue of Zebrafish, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The entire issue is available free online at www.liebertpub.com/zeb

8 Jan 2010

Preliminary studies show cancer vaccine may reduce tumor cells in CML patients

Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).

8 Jan 2010

Cell Medica signs R&D agreement with the Center for Cell and Gene Therapy

Cell Medica, a clinical cellular therapeutics company developing proven cell therapies which address important unmet clinical needs in oncology and infectious diseases, announced today the signing of an R&D agreement with the Center for Cell and Gene Therapy, a joint program of Baylor College of Medicine, Texas Children’s Hospital and The Methodist Hospital, Houston, Texas.

8 Jan 2010

Proteostasis Therapeutics enters into exclusive license agreement with New York University

Proteostasis Therapeutics announced today that it has entered into an exclusive license agreement with New York University for intellectual property related to discoveries from the laboratory of David Ron, M.D., Professor of Medicine and Julius Raynes Professor of Cell Biology at NYU Langone Medical Center’s Skirball Institute of Biomolecular Medicine.

8 Jan 2010

Patient enrollment in Tolerx's Phase 3 clinical study DEFEND-1 completed

Tolerx, Inc., today announced the completion of patient enrollment in its Phase 3 clinical study DEFEND-1, which is evaluating the safety and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with new-onset autoimmune type 1 diabetes.

8 Jan 2010

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Elixir Pharmaceuticals, Inc. announced today that its partner, Siena Biotech S.p.A., has commenced Phase 1 clinical testing of Elixir’s potent, first-in-class SIRT1 (sirtuin-1) inhibitor for the treatment of Huntington’s Disease.

8 Jan 2010

Gene modification of human embryonic stem cells may yield potential treatments for genetic diseases

Biologists have developed an efficient way to genetically modify human embryonic stem cells. Their approach, which uses bacterial artificial chromosomes to swap in defective copies of genes, will make possible the rapid development of stem cell lines that can both serve as models for human genetic diseases and as testbeds on which to screen potential treatments, they say.

8 Jan 2010

Murad launches new line of Anti-Aging Acne products for adults struggling with acne

Murad, Inc. has announced the launch of a new line of Anti-Aging Acne products for adults struggling with acne. The new Anti-Aging Acne line is the first comprehensive approach designed to restore a smooth, youthful complexion by addressing acne breakouts while diminishing the appearance of fine lines and wrinkles.

8 Jan 2010

Springer signs agreement with ISOBM to co-publish the journal Tumor Biology

Springer, a leading publisher in the fields of science, technology and medicine, has signed an agreement with the International Society of Oncology and BioMarkers (ISOBM) to co-publish the journal Tumor Biology starting in January 2010.

8 Jan 2010

Biovest International receives Orphan Drug Designation for its personalized lymphoma vaccine

Biovest International, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID®, Biovest’s personalized lymphoma vaccine. BiovaxID represents a new class of active immunotherapy and is one of the few select late-stage patient-specific cancer vaccines vying to be among the first to reach market.

8 Jan 2010

Epigenetic diagnosis and therapies, a new strategy for treating cancer

A tumor's genetic profile is often useful when diagnosing and deciding on treatment for certain cancers, but inexplicably, genetically similar leukemias in different patients do not always respond well to the same therapy.

7 Jan 2010

CRF awards $1.75 million in 11 new grants to researchers to find a cure for cystinosis

The Cystinosis Research Foundation of Irvine, Calif., announced it awarded $1.75 million in 11 new grants to researchers in the United States, Canada, Belgium and Italy who are working to find a cure for cystinosis, a rare, deadly metabolic and genetic disease that afflicts about 500 children and young adults in the U.S. and 2,000 worldwide.

7 Jan 2010

Muscular Dystrophy Association announces milestone grant to develop new treatments for ALS

Buoyed by the extraordinary progress being made by the ALS Therapy Development Institute, the Muscular Dystrophy Association today announced a new milestone-driven grant of $2.5 million, adding to the $18 million MDA already has invested with ALS TDI -- the world's only non-profit research center focused exclusively on developing treatments for amyotrophic lateral sclerosis (ALS).

7 Jan 2010

Rituximab treatment reduces patients' response to pneumonia vaccine

Researchers from Johns Hopkins University determined that immune responses to the tetanus vaccine were not changed when rituximab in combination with methotrexate (MTX) was compared with MTX alone in patients with rheumatoid arthritis (RA).

7 Jan 2010

Cell News and Research

Critically ill children with flu-like symptoms should be treated preemptively with antiviral medications

Business leaders should continue to monitor H1N1 risk management to alleviate major impact on costs and revenues

Chinese researchers become the world's fifth most prolific contributors to regenerative medicine

Ligand Pharmaceuticals receives $1 million as payment from N. V. Organon

Scientists identify gene underlying a disease that causes temporary paralysis of skeletal muscle

CSHL scientists explain how initiation of DNA replication is coordinated and controlled by kinase proteins

Zebrafish publishes special issue on cancer biology

Preliminary studies show cancer vaccine may reduce tumor cells in CML patients

Cell Medica signs R&D agreement with the Center for Cell and Gene Therapy

Proteostasis Therapeutics enters into exclusive license agreement with New York University

Patient enrollment in Tolerx's Phase 3 clinical study DEFEND-1 completed

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Gene modification of human embryonic stem cells may yield potential treatments for genetic diseases

Murad launches new line of Anti-Aging Acne products for adults struggling with acne

Springer signs agreement with ISOBM to co-publish the journal Tumor Biology

Biovest International receives Orphan Drug Designation for its personalized lymphoma vaccine

Epigenetic diagnosis and therapies, a new strategy for treating cancer

CRF awards $1.75 million in 11 new grants to researchers to find a cure for cystinosis

Muscular Dystrophy Association announces milestone grant to develop new treatments for ALS

Rituximab treatment reduces patients' response to pneumonia vaccine

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News